Joseph K. Belanoff - Concepedia

Author

Joseph K. Belanoff

Also Known As

J BELANOFF, J Belanoff, J. Belanoff, J. K. Belanoff, JOSEPH BELANOFF, Joseph Belanoff, Joseph K Belanoff, Joseph K. Belanoff

Publications

3.7K

Citations

H-Index

Concepts

All Affiliations

Corcept Therapeutics (United States)Stanford University Leiden University Medical Center Radboud University Nijmegen Experimental Medicine and Biology Institute

About

Joseph K. Belanoff is an author at Corcept Therapeutics (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	24	2.1K
2	Social Sciences	9	9	1.2K
3	Health Sciences	5	5	138
4	Natural Sciences	1	1	26
5	Behavioral Sciences	1	1	217

Joseph K. Belanoff

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. Bruce N. Cronstein, Richard I. Levin, Joseph K. Belanoff, Journal of Clinical Investigation InflammationEndothelial Cell PathobiologyMedicinal ChemistryAnti-inflammatoryEndothelial Cells	1986	418
An open label trial of C-1073 (mifepristone) for psychotic major depression* Joseph K. Belanoff, Anthony J. Rothschild, Frederick Cassidy, Biological Psychiatry PsychiatryPsychotropic MedicationPsychopharmacologySchizophreniaPsychology	2002	314
Rapid Reversal of Psychotic Depression Using Mifepristone Joseph K. Belanoff, Benjamin Flores, Michelle Kalezhan, Journal of Clinical Psychopharmacology PsychiatryMedicineDepressionSchizophreniaPsychopharmacology	2001	281
Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals Leandro F. Vendruscolo, David Estey, Vivian Goodell, Journal of Clinical Investigation NeuropsychologySubstance UsePsychopharmacologyGlucocorticoidGlucocorticoid Receptor	2015	217
Successful Long-Term Treatment of Refractory Cushing’s Disease with High-Dose Mifepristone (RU 486) James W. Chu, Dwight F. Matthias, Joseph K. Belanoff, The Journal of Clinical Endocrinology & Metabolism	2001	189
Cortisol Activity and Cognitive Changes in Psychotic Major Depression Joseph K. Belanoff, Michelle Kalehzan, Brenda Sund, American Journal of Psychiatry	2001	180
Mifepristone versus Placebo in the Treatment of Psychosis in Patients with Psychotic Major Depression Charles DeBattista, Joseph K. Belanoff, Steven Glass, Biological Psychiatry PsychopathologyMifepristone Versus PlaceboPsychiatryPsychotic DisorderMedicine	2006	159
Differential targeting of brain stress circuits with a selective glucocorticoid receptor modulator Ioannis Zalachoras, René Houtman, Erika Atucha, Proceedings of the National Academy of Sciences	2013	117
Combined Analysis of Mifepristone for Psychotic Depression: Plasma Levels Associated With Clinical Response Thaddeus Block, Harvey Kushner, Ned H. Kalin, Biological Psychiatry	2018	78
Efficacy and Safety of Mifepristone for the Treatment of Psychotic Depression Christine Blasey, Thaddeus Block, Joseph K. Belanoff, Journal of Clinical Psychopharmacology Psychotic DepressionPsychotropic MedicationMifepristone Plasma ConcentrationsMifepristone Plasma ConcentrationPsychopharmacology	2011	70

Page 1